Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2020 Nov 1;105(11):2659-2663.
doi: 10.3324/haematol.2019.242826.

Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review and meta-analysis

Jan Philipp Bewersdorf  1 , Smith Giri  2 , Rong Wang  3 , Robert T Williams  4 , Martin S Tallman  5 , Amer M Zeidan  1 , Maximilian Stahl  6
Affiliations
Meta-Analysis

Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review and meta-analysis

Jan Philipp Bewersdorf et al. Haematologica. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Flow chart showing study selection as per the MOOSE guidelines. Figure 1 illustrates the search strategy and stepwise process of the study selection used in this meta-analysis. MEDLINE via Ovid, Ovid EMBASE, Scopus, the COHRANE registry of clinical trials (CENTRAL), and the Web of Science electronic databases were searched with no language restriction from inception through August 2019, using the following combination of free-text terms linked by Boolean operators: “acute myeloid leukemia” OR “AML” OR “myelodysplastic syndrome” OR “MDS” AND “venetoclax”. Two authors (MS and JPB) independently screened the titles and abstracts of all retrieved studies for eligibility and removed any duplicate records. In a second step, full texts of the potentially eligible studies were reviewed for the final eligibility. Reviews, basic science articles and articles with an insufficient patient number (<5 patients) were excluded. Furthermore, we excluded studies that i) lacked information on either overall response rate (ORR) or complete resposnse (CR) rate, ii) review articles, editorials, and correspondence letters that did not report independent data, iii) case series and studies reporting outcomes on fewer than five patients, iiii) studies that did were not conducted in acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) patients.
Figure 2.
Figure 2.
Response to venetoclax in relapsed/refractory acute myeloid leukemia (R/R-AML). Forest plots of odds ratios (squares, proportional to study weights used in meta-analysis, 95% confidence intervals) of response for venetoclax alone and in combination hypomethylating agents (HMA) or low-dose cytarabine (LDAC) with the summary measures (center line of diamond) and associated confidence intervals (lateral tips of diamond). Odds ratios for overall response rate (ORR), combined complete response (CR) and complete response with incomplete count recovery (CRi) rate and CR alone are shown in panel A, B and C respectively. Odds ratio for the ORR for patients, who received prior HMA therapy, is shown in panel D.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. DiNardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133(1):7-17. - PMC - PubMed
    1. Wei AH, Strickland SA, Hou JZ, et al. Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib/II study. J Clin Oncol. 2019;37(15):1277-1284. - PMC - PubMed
    1. Ganzel C, Sun Z, Cripe LD, et al. Very poor long-term survival in past and more recent studies for relapsed AML patients: The ECOGACRIN experience. Am J Hematol. 2018;93(8):1074-1081. - PMC - PubMed
    1. Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424-447. - PMC - PubMed
    1. Goldberg AD, Horvat TZ, Hsu M, et al. Venetoclax combined with either a hypomethylating agent or low-dose cytarabine shows activity in relapsed and refractory myeloid malignancies. Blood. 2017; 130(Supplement 1):1353.

MeSH terms